Employees: 586
Size Synmosa Biopharma (4114.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $423M, the 488th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$26.30 on 18 Nov 2026.
Performance Over six months the shares fell 1.3%, against -26.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 21.0% over the last twelve months (peer median +3.4%); the operating margin is 10.2% (peer median -10.6%).
Valuation It trades at 2.2× enterprise value to sales against a peer median of 3.3× (7th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.1 points below its cost of capital (5.0% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$7.39B | NT$6.19B | NT$5.55B | NT$5.14B | NT$4.39B |
| Revenue growth | — | +12% | +8% | +17% | — |
| Gross profit | NT$2.72B | NT$2.54B | NT$2.25B | NT$1.97B | NT$1.69B |
| EBITDA | NT$1.12B | NT$1.12B | NT$1.08B | NT$956M | NT$780M |
| Net income | NT$832M | NT$822M | NT$685M | NT$595M | NT$799M |
| Free cash flow | NT$196M | NT$134M | NT$535M | NT$262M | NT$449M |
| Capital expenditure | NT$340M | NT$281M | NT$270M | NT$270M | NT$184M |
| Total debt | NT$4.19B | NT$2.52B | NT$2.55B | NT$2.44B | NT$3.37B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4114.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.2% | -11.8% | 10th lowest of 21 |
| 6-month return | -1.3% | -26.3% | 5th highest of 21 |
| Distance from 52-week high | -16.2% | -51.3% | highest of 21 |
| Revenue growth (TTM) | +21.0% | +3.4% | 7th highest of 19 |
| Operating margin | 10.2% | -10.6% | 3rd highest of 19 |
| EV / Sales | 2.2× | 3.3× | 7th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 5.4% | 0.6% | 3rd most demanding of 7 |
| Growth delivered (Del g) | +15.3% | +4.3% | highest of 7 |
| Hurdle (Req g minus delivered) | -9.8 pp | +1.3 pp | 3rd least demanding of 7 |
| ROIC minus cost of capital | -0.1 pp | -8.2 pp | 7th highest of 18 |
| EV / EBITDA | 14.5× | n/a | — |
| Net debt / EBITDA | 1.1× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Synmosa Biopharma 4114.TWO | Taiwan | $423M | -1% | +21% | 10% | 2.2× | 5.4% | +15.3% |
| Beijing Foyou Pharma 601089.SS | China | $423M | -27% | +5% | 10% | 0.2× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $423M | -26% | +9% | 13% | 0.7× | -15.4% | +7.2% |
| Tevogen TVGN | United States | $422M | -38% | n/a | n/a | n/a | n/a | n/a |
| Hyundai Bioscience 048410.KS | South Korea | $424M | -50% | +78% | -580% | 164.0× | n/a | n/a |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $421M | -31% | +1% | -39% | 7.1× | n/a | n/a |
| Teyi Pharmaceutical 002728.SZ | China | $419M | -12% | -7% | 7% | 3.2× | 24.4% | +8.0% |
| Ovid Therapeutics OVID | United States | $427M | -5% | -78% | -4,700% | 208.3× | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $427M | +9% | +69% | -16% | 6.2× | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $427M | +4% | -4% | 3% | 1.2× | 10.6% | +1.4% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $430M | -30% | +14% | 5% | 2.2× | 1.4% | -1.3% |
| Phathom Pharmaceuticals PHAT | United States | $431M | -55% | +87% | -9% | 2.9× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $433M | -48% | +51% | 27% | 3.4× | -0.2% | +14.5% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $433M | -47% | +35% | 4% | 1.1× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $433M | -42% | -14% | -12% | 2.9× | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $412M | +64% | +6,162% | -194% | 119.7× | n/a | n/a |
| Rezolute RZLT | United States | $411M | +32% | n/a | n/a | n/a | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $410M | -49% | -88% | -676% | 4.7× | n/a | n/a |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $437M | -8% | -17% | -28% | 10.6× | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $437M | -12% | -49% | 5% | 2.1× | -5.6% | -5.6% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $437M | -16% | -5% | -29% | 4.2× | n/a | n/a |